

Dual Antiplatelet Therapy in **Coronary Artery Disease**

NEW GUIDELINES AND BEYOND



You are cordially invited to attend ***Dual Antiplatelet Therapy in Coronary Artery Disease: New Guidelines and Beyond***, a webinar held live online, hosted by the **American Association of Cardiologists of Indian Origin (AACIO)**. The activity will review the 2016 ACC/AHA guideline update for the use of DAPT in CAD and outline the real-world evidence for these recommendations.

Join us for one of these live virtual webinars!

Saturday, July 25, 2020
1:00 - 2:00 PM ET


OR

Saturday, August 29, 2020
1:00 - 2:00 PM ET

For full accreditation information and to register, visit:

www.rockpointe.com/cadwebinar

STEERING COMMITTEE



Tracy Y. Wang, MD, MHS, MSc, FACC, FAHA

Associate Professor of Medicine
Director of Health Services Research
Duke University
Durham, NC



Marlene S. Williams, MD, FACC

Director, Cardiac Intensive Care Unit
Johns Hopkins Bayview Medical Center
Associate Professor of Medicine
Division of Cardiology
Johns Hopkins University
Baltimore, MD

TOPICS INCLUDE:

- Guidelines on the Use of DAPT in CAD
- What's New Since the Guidelines?
- Patient Education

ACCREDITATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of North Texas Health Science Center and Rockpointe. The University of North Texas Health Science Center is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

The University of North Texas Health Science Center designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Jointly provided by the University of North Texas Health Science Center and Rockpointe

This program is supported by an unrestricted educational grant from AstraZeneca.